KRAS and non-small cell lung carcinoma: In agreement with the results in cell line models, honokiol significantly suppressed lung tumor burden and activation of EGFR, Akt and STAT3 in NNK-induced lung tumor model bearing KRAS mutation [52–54], suggesting that honokiol could target EGFR in NSCLC patients with a history of tobacco smoke and KRAS mutation.